TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2188797

Group type: EXPERIMENTAL
Intervention: Intramuscular flupenthixol decanoate (5 to 10 mg/fortnight)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Oral amitriptyline (75 to 150 mg/day)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 57
Study: 7002374

Group type: EXPERIMENTAL
Intervention: 400 microgram beclomethasone dipropionate a day for 2 weeks
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 31125404

Group type: EXPERIMENTAL
Intervention: Reconstituted alfalfa hay (RAH)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Reconstituted beet pulp (RBP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Corn silage (CS)
Number of subjects: 54
Study: 26046808

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with initial restrictive pressures (IRP) of 40 or 60 mmHg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control session (no blood flow restriction)
Number of subjects: 34
Study: 25793351

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 98

Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 98
Study: 24261310

Group type: EXPERIMENTAL
Intervention: Preventive laser therapy (red or infrared) for 5 days starting on the 1st day of infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Therapeutic laser therapy (red or infrared) only if mucositis developed
Number of subjects: 40
Study: 21074333

Group type: EXPERIMENTAL
Intervention: MRI scans (initial and follow-up)
Number of subjects: 51
Study: 19476649

Group type: EXPERIMENTAL
Intervention: NFG (n = 19)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: IFG (n = 19)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Diabetes (n = 35)
Number of subjects: 73
Study: 17298645

Group type: EXPERIMENTAL
Intervention: Minnesota day clinic treatment
Number of subjects: 148

Group type: COMPARATOR
Intervention: Public out‐patient alcohol clinic treatment
Number of subjects: 148
Study: 15129791

Group type: EXPERIMENTAL
Intervention: Device-based testing
Number of subjects: 74

Group type: COMPARATOR
Intervention: External cardiac defibrillation
Number of subjects: 74
Study: 11295901

Group type: EXPERIMENTAL
Intervention: Spinal manipulation with exercise
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: MedX rehabilitative neck exercise
Number of subjects: 191

Group type: COMPARATOR
Intervention: Spinal manipulation alone
Number of subjects: 191
Study: 10633536

Group type: EXPERIMENTAL
Intervention: Upright posture (U) for 20 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sitting posture (S) for 20 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lying posture (L) for 20 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Upright posture (U)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sitting posture (S) and Lying posture (L)
Number of subjects: 24
Study: 8958495

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 41

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 41
Study: 7555292

Group type: EXPERIMENTAL
Intervention: Total McKee-Farrar hip replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperated arthritic hips and normal hips (control group)
Number of subjects: 0
Study: 3893128

Group type: EXPERIMENTAL
Intervention: 135 mEq/l sodium dialysate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 143 mEq/l sodium dialysate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sodium gradient dialysate
Number of subjects: 7

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 7
Study: 28074421

Group type: EXPERIMENTAL
Intervention: Directly observed combination antiretroviral therapy (DOT-cART)
Number of subjects: 356

Group type: COMPARATOR
Intervention: No DOT
Number of subjects: 356
Study: 26324250

Group type: COMPARATOR
Intervention: Nicotine concentration of 0 mg/mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine concentration of 8 mg/mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine concentration of 18 mg/mL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nicotine concentration of 36 mg/mL
Number of subjects: 16
Study: 25195084

Group type: EXPERIMENTAL
Intervention: 5th generation troponin T reporting
Number of subjects: 2000

Group type: COMPARATOR
Intervention: 4th generation troponin T reporting
Number of subjects: 2000
Study: 22464410

Group type: EXPERIMENTAL
Intervention: OC+SPL (2 mg chlormadinone acetate/30 mcg ethinylestradiol combined with spironolactone)
Number of subjects: 50

Group type: COMPARATOR
Intervention: OC (2 mg chlormadinone acetate/30 mcg ethinylestradiol)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OC
Number of subjects: 50

Group type: COMPARATOR
Intervention: OC+SPL
Number of subjects: 50
Study: 20506712

Group type: EXPERIMENTAL
Intervention: Living Probiotic (LP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Killed Probiotic (KP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Positive Lactobacillus colonization
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall comparison among three groups
Number of subjects: 150
Study: 18555732

Group type: EXPERIMENTAL
Intervention: Various diagnostic labels for shoulder pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abolishing the use of diagnostic labels
Number of subjects: 0
Study: 15701355

Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acceptance-based strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitor-only group
Number of subjects: 0
Study: 11939435

Group type: EXPERIMENTAL
Intervention: Isoprenaline 0.05 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline 0.075 microg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adrenaline 0.5 microg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline (both doses)
Number of subjects: 0
Study: 10369554

Group type: EXPERIMENTAL
Intervention: Nd:YAG hyperthermia therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 50
Study: 7552586

Group type: EXPERIMENTAL
Intervention: Purified zinc oxide fume exposure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 14
Study: 2248080

Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 31693683

Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Sedentary behavior patterns
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Sedentary time and bout length
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Being a student
Number of subjects: 385
Study: 30333315

Group type: EXPERIMENTAL
Intervention: Ketoprofen 75 mg by mouth 3 times daily for 4 months
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 55
Study: 27149048

Group type: EXPERIMENTAL
Intervention: MMRVAMP (alternative process)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: MMRV (currently licensed)
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: MMRVAMP
Number of subjects: 1412

Group type: COMPARATOR
Intervention: MMRV
Number of subjects: 1412
Study: 25264726

Group type: EXPERIMENTAL
Intervention: VATS lobectomy (A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open resection (B)
Number of subjects: 32
Study: 22438308

Group type: EXPERIMENTAL
Intervention: Electronically monitored adherence
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Shea self-report adherence
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Days adherent
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intervals adherent
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Electronic monitor
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Shea self-report
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Other measures
Number of subjects: 180
Study: 20716712

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18676180

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 234

Group type: COMPARATOR
Intervention: Telephone
Number of subjects: 234
Study: 15807876

Group type: EXPERIMENTAL
Intervention: GH 0.1 IU/kg/day [0.033 mg/kg/day]
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH 0.2 IU/kg/day [0.067 mg/kg/day]
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14632341

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg kg(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone (5 mg kg(‐1))
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 50
Study: 11515626

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain GG
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8874372

Group type: EXPERIMENTAL
Intervention: Glipizide (maximum daily dosage)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Glyburide (maximum daily dosage)
Number of subjects: 55

Group type: COMPARATOR
Intervention: First-generation sulfonylurea agents
Number of subjects: 55
Study: 1531566

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20
Study: 6394020

Group type: EXPERIMENTAL
Intervention: Amniocentesis group (N = 25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No amniocentesis group (N = 22)
Number of subjects: 47
Study: 31815640

Group type: EXPERIMENTAL
Intervention: mobile Link - A theory-based messaging intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30214718

Group type: EXPERIMENTAL
Intervention: Audit with feedback and academic detailing
Number of subjects: 1802
Study: 27370156

Group type: EXPERIMENTAL
Intervention: Portable bladder scanner (BS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CBCT only pre-RT)
Number of subjects: 22
Study: 24977342

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 399

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 399
Study: 21914632

Group type: EXPERIMENTAL
Intervention: Randomized practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grouped practice
Number of subjects: 0
Study: 19462524

Group type: EXPERIMENTAL
Intervention: IL1A+4845(*)TT genotype
Number of subjects: 532

Group type: COMPARATOR
Intervention: Higher baseline CD4 T-cell counts
Number of subjects: 532

Group type: COMPARATOR
Intervention: IL1A-889 and IL1A+4845 genotypes
Number of subjects: 532
Study: 18186680

Group type: EXPERIMENTAL
Intervention: New ureteroscope (Flex‐X, Karl Storz)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard ureteroscope
Number of subjects: 32
Study: 15727639

Group type: EXPERIMENTAL
Intervention: PDT with 20 J cm(‐2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PDT with 10 J cm(‐2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PDT with 5 J cm(‐2)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Keratolytic pretreatment
Number of subjects: 29
Study: 12486868

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9653784

Group type: EXPERIMENTAL
Intervention: Interviews conducted by responsible caregivers
Number of subjects: 52

Group type: COMPARATOR
Intervention: Interviews conducted by interviewers from other providers
Number of subjects: 52
Study: 8587620

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Withdrawal of sodium bicarbonate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sodium-restricted diet in patients treated with tiopronin
Number of subjects: 13
Study: 2650798

Group type: EXPERIMENTAL
Intervention: Gold and hydroxychloroquine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Gold and placebo
Number of subjects: 101
Study: 1172599

Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin tablets (Novodigal¿)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PETN/beta‐acetyldigoxin tablets (Nitro‐Novodigal¿)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: oxyfedrin/beta‐acetyldigoxin tablets (ildamen¿‐Novodigal¿)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin liquid
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin in alcoholic solution
Number of subjects: 11

Group type: COMPARATOR
Intervention: digoxin solution
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: beta‐acetyldigoxin tablets
Number of subjects: 11

Group type: COMPARATOR
Intervention: digoxin tablets (Digacin¿)
Number of subjects: 11
Study: 29559283

Group type: EXPERIMENTAL
Intervention: 74 Gy/37 fractions
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: 60 Gy/20 fractions
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: 57 Gy/19 fractions
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Ki67
Number of subjects: 346
Study: 27441461

Group type: EXPERIMENTAL
Intervention: D-cycloserine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26297500

Group type: EXPERIMENTAL
Intervention: 4-month hypocaloric diet (HCD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (age- and BMI-matched subjects)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HCD
Number of subjects: 17
Study: 23190425

Group type: EXPERIMENTAL
Intervention: TAVI (Edwards Sapien or CoreValve device)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TAVI (Edwards Sapien device)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TAVI (CoreValve device)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TAVI (pre-TAVI EROA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TAVI (pre-TAVI MR index)
Number of subjects: 35
Study: 22004614

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi)
Number of subjects: 0
Study: 20108513

Group type: EXPERIMENTAL
Intervention: Hexvix blue light cystoscopy (BLC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard white light cystoscopy (WLC)
Number of subjects: 20
Study: 16431398

Group type: EXPERIMENTAL
Intervention: Controlled release diltiazem pellets
Number of subjects: 6

Group type: COMPARATOR
Intervention: Herbesser SR
Number of subjects: 6
Study: 12436805

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) - ten sessions
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fluoxetine - 20 mg daily
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined therapy (CBT plus fluoxetine)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 108
Study: 10359466

Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy (8 weekly sessions)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care from psychiatrist (Control)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy
Number of subjects: 110
Study: 8537197

Group type: EXPERIMENTAL
Intervention: 0.5 mg/ml of Mitomycin C (MMC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 0.2 mg/ml of Mitomycin C (MMC)
Number of subjects: 89
Study: 1743242

Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS) with phasic release of glyceryl trinitrate (GTN)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sublingual GTN 0.8 mg
Number of subjects: 8
Study: 6750067

Group type: EXPERIMENTAL
Intervention: Cyclacillin, administered in three divided doses (three times a day) for ten days
Number of subjects: 363

Group type: COMPARATOR
Intervention: Amoxicillin, similar regimen for ten days
Number of subjects: 363
Study: 31859153

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic training only
Number of subjects: 40
Study: 31148988

Group type: EXPERIMENTAL
Intervention: Fenugreek 2 g/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glibenclamide 5 mg once daily
Number of subjects: 12
Study: 28277854

Group type: EXPERIMENTAL
Intervention: Mepolizumab 75 mg intravenous (IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneous (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab groups (75 mg IV and 100 mg SC)
Number of subjects: 0
Study: 26621118

Group type: EXPERIMENTAL
Intervention: XM17 (300 IU subcutaneous)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gonal-f(®) (300 IU subcutaneous)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: XM17
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gonal-f(®)
Number of subjects: 36
Study: 22989158

Group type: EXPERIMENTAL
Intervention: Sitting in a chair for 2 hours postoperatively (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine positioning for 2 hours postoperatively (group 2)
Number of subjects: 40
Study: 22498923

Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 59

Group type: COMPARATOR
Intervention: Informational video
Number of subjects: 59
Study: 19179915

Group type: EXPERIMENTAL
Intervention: Lumbar belt (BWG)
Number of subjects: 197
Study: 17545139

Group type: EXPERIMENTAL
Intervention: Video intervention (set of 10 videos, workbook, weekly telephone coaching sessions)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Basic education intervention (educational booklet and biweekly check-in telephone calls)
Number of subjects: 32
Study: 15457551

Group type: EXPERIMENTAL
Intervention: IFN-alpha2b + ribavirin (treatment group = TG)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Old treatment control group (OTCG) with IFN-alpha2b
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (CG) with no treatment
Number of subjects: 101
Study: 11466162

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb) administered for 30 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9534633

Group type: EXPERIMENTAL
Intervention: Deeply anaesthetised group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Awake group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Anaesthetised group
Number of subjects: 66
Study: 7697239

Group type: EXPERIMENTAL
Intervention: TOPA (10% lidocaine spray and 0.25% bupivocaine gargle)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 6
Study: 2689014

Group type: EXPERIMENTAL
Intervention: Terbinafine 125 mg b.i.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Griseofulvin 250 mg (microsize) b.i.d.
Number of subjects: 36
Study: 1098216

Group type: EXPERIMENTAL
Intervention: Urokinase (UK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-hour Urokinase (12h-UK)
Number of subjects: 0
Study: 31735564

Group type: EXPERIMENTAL
Intervention: Maternal voice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no maternal voice)
Number of subjects: 60
Study: 31366752

Group type: EXPERIMENTAL
Intervention: Life‐Trouble Inclusion Scale-based care planning tool
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 28982672

Group type: EXPERIMENTAL
Intervention: Extended-release torsemide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Immediate-release torsemide
Number of subjects: 10
Study: 26447524

Group type: EXPERIMENTAL
Intervention: Standardized and supervised exercise program over 6 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 33
Study: 22892141

Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy (CBT) after psycho-education materials
Number of subjects: 21

Group type: COMPARATOR
Intervention: Psycho-education materials
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baseline waitlist
Number of subjects: 21
Study: 21493672

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Late pubertal induction with ethinylestradiol (starting at age 14)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Oxandrolone alone, late induction alone, and oxandrolone plus late induction
Number of subjects: 106
Study: 19621690

Group type: EXPERIMENTAL
Intervention: 6 g AzOAB: Azithromycin 500 mg twice daily for 6 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 2 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 3 g AzOAB: Azithromycin 500 mg twice daily for 3 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 1 week
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1.5 g AzOAB: Azithromycin 250 mg twice daily for 3 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 1 week
Number of subjects: 84
Study: 16434269

Group type: EXPERIMENTAL
Intervention: Endoscopic harvest
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional harvest with cautery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional harvest with harmonic scalpel
Number of subjects: 54
Study: 15262041

Group type: EXPERIMENTAL
Intervention: Passive intermittent hypoxia (15 sessions, 3-5 min hypoxic periods at 14-10% oxygen with 3-min normoxic intervals)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normoxia (control group, inhaled normoxic air)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Passive intermittent hypoxia
Number of subjects: 16
Study: 12536729

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 67
Study: 9292383

Group type: EXPERIMENTAL
Intervention: Positive feedback given to boys with ADHD after the first interaction.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positive feedback given to comparison boys after the first interaction.
Number of subjects: 60
Study: 8279244

Group type: EXPERIMENTAL
Intervention: Alfentanil 40 micrograms.kg‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms.kg‐1 + lidocaine 1 mg.kg‐1
Number of subjects: 45